Xolair Treatment for Milk Allergic Children
Part of paid clinical trials in Stanford, California.
- Sponsor
- Boston Children's Hospital
- Study ID
- NCT00968110
- Phase
- EARLY_PHASE1
- Status
- Completed
Conditions
- Milk Allergy
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Years - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- omalizumab — DRUGDosing table established for omalizumab
Study Details
This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.
Key Dates
- Start date
- Mar 31, 2009
- Status verified
- Sep 2018
- Primary completion
- Apr 30, 2017
- Completion
- Apr 30, 2017
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: XolairAll patients will receive Xolair treatment for 16 weeks.
Primary Outcome Measure
The major goal of this study is to assess the safety of Xolair in young children, and the safety of oral desensitization in patients pretreated with Xolair [ Time Frame: week 53 ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford Uneiversity Medical Center | Stanford | California | 94305 | - |
| Children's Hosptial Boston | Boston | Massachusetts | 02115 | - |